Management of venous thromboembolism in cancer patients: ESMO Clinical Recommendations

Annals of Oncology

Volumn 20, Issue SUPPL. 4, 2009, Pages

  Mandala M ^a   Falanga, A ^a   Roila, F ^b  

^a OSPEDALI RIUNITI   (Italy)

^b S MARIA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ARTICLE; CANCER INCIDENCE; CANCER PATIENT; CANCER RISK; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; HUMAN; LAPAROSCOPY; LAPAROTOMY; MORBIDITY; MORTALITY; PALLIATIVE THERAPY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RECURRENT DISEASE; SINGLE DRUG DOSE; THORACOSCOPY; THORACOTOMY; THORAX RADIOGRAPHY; TREATMENT DURATION; VENA CAVA FILTER; VENOUS THROMBOEMBOLISM;

EID: 66549111574     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp167     Document Type: Article

References (7)

1. Chew HK, Wun T, Harvey D et al. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 2006; 166: 458-464.
2. Falanga A, Zacharski L. Deep vein thrombosis in cancer: The scale of the problem and approaches to management. Ann Oncol 2005; 16: 696-701.
3. Khorana AA, Kuderer NM, Culakova E et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008; 15: 4902-4907.
4. Mandala M, Falanga A, Piccioli A et al. Venous thromboembolism and cancer: Guidelines of the Italian Association of Medical Oncology (AIOM). Crit Rev Oncol Hematol 2006; 59: 194-204.
5. Lyman GH, Khorana AA, Falanga A et al. American Society of Clinical Oncology guideline: Recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007; 25: 5490-5505.
6. Lee A, Levine M, Baker RI et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349: 146-153.
7. Meyer G, Marjanovic Z, Valcke J et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: A randomized controlled study. Arch Intern Med 2002; 162: 1729-1735.